Shots:
- Vertex announced topline results from its P‑II study of selective NaV1.8 inhibitor VX‑993 in 367 pts with acute pain post-bunionectomy; VX‑993 did not achieve a statistically significant improvement in SPID48 vs placebo
- VX‑993 was safe and well tolerated at all doses, with AEs mostly mild/moderate; no SAEs related to VX‑993 and no discontinuations due to AEs; most common AEs (>5%) included nausea, headache, dizziness, and vomiting
- Based on results and totality of preclinical and prior data, Vertex will not advance VX‑993 as monotx. in acute pain, the hydrocodone/acetaminophen reference arm showed statistically significant SPID48 improvement vs PBO
Ref: Vertex | Image: Vertex| Press Release
Related News:- Vertex Presents Long-Term CLIMB Trial Program Data of Casgevy (Exagamglogene Autotemcel) to Treat Hemoglobinopathies at EHA 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
